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To evaluate the impact of tamoxifen on subjective and psychosexual well-being in breast cancer patients in relation to type of
prior chemotherapy and menopausal status. Longitudinal interview study in breast cancer patients during and after adjuvant
tamoxifen use. Menopausal status was deﬁned by last menstrual period and serum oestradiol and FSH levels. Gynaecology
outpatient clinic, Tertiary Referral Hospital, January 1995 to September 1999. Breast cancer patients 556 years of age,
participating in a randomised trial comparing adjuvant high-dose (n=45) and standard-dose (n=53) chemotherapy, followed by
radiotherapy and tamoxifen. Relative incidence and correlation of subjective and psychosexual symptoms during and after
tamoxifen. During tamoxifen the most frequent complaints were hot ﬂushes (85%), disturbed sleep (55%), vaginal dryness
and/or dyspareunia (47%), decreased sexual desire (44%) and musculo-skeletal symptoms (43%). Disturbed sleep correlated
with hot ﬂushes (P50.0005) and concentration problems (P50.05). Decreased sexual interest correlated with vaginal dryness
(P50.0005) and/or dyspareunia (P50.0005). In the high-dose group more patients became postmenopausal (95% vs 33%)
and more patients reported symptoms than in the standard-dose group (P50.05). After discontinuation of tamoxifen,
symptoms decreased signiﬁcantly. However, hot ﬂushes, disturbed sleep and vaginal dryness persisted more often in patients
who remained postmenopausal after high-dose chemotherapy (P50.05). Overall, during tamoxifen patients reported many
symptoms. More patients become postmenopausal after high-dose chemotherapy, and they remain often symptomatic after
tamoxifen.
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Tamoxifen plays an important role as adjuvant therapy after
surgery for primary breast cancer in premenopausal and postmeno-
pausal women (Early Breast Cancer Trialists’ Group, 1998). In
addition, tamoxifen is prescribed for the prevention of breast
cancer in high risk women in the United States since the Breast
Cancer Prevention Trial (BCPT) of the National Surgical Adjuvant
Breast and Bowel Project (NSABP) showed a breast cancer risk
reduction in healthy women over the age of 35 years at high risk
for breast cancer (Fisher et al, 1998), although two European
studies could not conﬁrm these results (Powles et al, 1998;
Veronesi et al, 1998).
Being a drug with both agonistic and antagonistic properties,
tamoxifen can have oestrogen as well as anti-oestrogen effects on
different sites and tissues, depending on the ambient oestradiol
concentration. Side effects of tamoxifen have been studied mainly
in postmenopausal women (No authors listed, 1985; Fisher et al,
1989; Love, 1989, 1992; Love et al, 1991; Ragaz, 1997), while only
a few studies included also women under 50 years of age. Although
an important component of quality of life, few studies have paid
attention to the impact of tamoxifen on sexual functioning (Ganz
et al, 1995, 1998; Day et al, 1999). Moreover, in younger women,
induction of menopause as a result of high-dose chemotherapy
might have a negative impact on quality of life and sexual func-
tioning. The present study was performed to assess the impact of
tamoxifen on breast cancer patients under 56 years of age following
adjuvant standard- or high-dose chemotherapy. We collected
prospective information on subjective side effects and sexual func-
tioning during and after tamoxifen use and related symptoms to
type of chemotherapy and menopausal status as deﬁned by last
menstrual period and serum levels of follicle stimulating hormone
(FSH) and oestradiol.
PATIENTS AND METHODS
Patients
Between January 1995 and September 1995 all breast cancer
patients 556 years of age with four or more tumour positive
axillary lymph nodes treated at the Department of Medical Oncol-
ogy, University Hospital Groningen, The Netherlands, and
participating in the Dutch randomised study comparing stan-
dard-dose and high-dose chemotherapy, were referred to the
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randomly assigned to receive either ﬁve cycles of standard-dose
5-ﬂuorouracil (500 mg m
72), epirubicin (90 mg m
72) and cyclo-
phosphamide (500 mg m
72) (FEC) or four cycles of FEC plus
one cycle of high-dose chemotherapy (cyclophosphamide 6 g
m
72, thiotepa 480 mg m
72 and carboplatin 1.6 g m
72), followed
by peripheral blood progenitor stem-cell rescue. In both treatment
arms chemotherapy was followed by locoregional radiotherapy
and 2 years of daily 40 mg tamoxifen (de Vries et al, 1996).
The study was approved by the Medical Ethical Committee of
the University Hospital Groningen. All patients gave informed
consent.
Methods
Patients were seen after completion of chemotherapy, at 6
monthly intervals during tamoxifen treatment and again 3–6
months after cessation of tamoxifen. Symptoms during and after
tamoxifen were compared, to evaluate the effect of tamoxifen
on the symptoms. Patients were excluded for analysis if tumour
relapse occurred. At each visit a structured interview on the basis
of two self-reported questionnaires was performed by the same
gynaecologist (MM). The interviewer is an experienced clinician
and sexuologist, trained in taking interviews. Interview items were
derived from, at that time available, reports on side effects of
tamoxifen (No authors listed, 1985; Fisher et al, 1989; Love,
1989, 1992; Love et al, 1991; Powles et al, 1994). The ﬁrst part
of the interview contained items of physical, mood-related and
psychological symptoms associated with tamoxifen as well as
symptoms associated with menopause (Appendix 1). Depressive
symptoms were deﬁned as reporting three or more of the follow-
ing: feeling miserable and sad, lack of enjoyment, loss of interest,
loss of vitality, loss of initiative, life not worth living. The second
part of the interview contained the major components of sexual
functioning: sexual interest (desire and ability to enjoy sex), activ-
ity (frequency, ability to perform sexual activity), and pleasure or
discomfort (pain, vaginal dryness) (Appendix 2) (McCoy and
Davidson, 1985; Wilmoth, 1993; Greendale et al, 1996; Thirlaway
et al, 1996). With every question, patients were asked to compare
the present situation with the situation before the cancer treat-
ment. Only patients with a sexual partner were interviewed
about sexual functioning.
As ovarian failure plays a major role in well-being and sexual
function (McCoy and Davidson, 1985; Greendale et al, 1996), a
menstrual history was recorded and at each visit serum levels of
FSH (Amerlite FSH Assay, Johnson & Johnson Clinical Diagnostics
Ltd., Amersham, UK) and oestradiol were determined by radio-
immunoassay, as described previously (Jurjens et al, 1975). As
tamoxifen can result in amenorrhoea without ovarian
failure (Mourits et al, 1999), menopause was deﬁned as no
menstrual periods in the preceding 12 months and FSH levels
430 nmol l
71 and oestradiol levels 50.10 nmol l
71.
Statistics
Data analysis was performed using software (SPSS 9.0; SPSS Inc:
Chicago, USA). Variance of paired symptom score differences were
analysed using the test of Pitman. Difference was corrected for
continuity. Comparability in frequencies was analysed using the
w
2 test. Only P-values 50.05 were considered signiﬁcant.
RESULTS
Patient characteristics
A total of 116 patients were referred. Eighteen patients refused to
take part in the interviews. Ninety-eight patients were enrolled
for interviews and their characteristics are summarised in Table
1. Forty-ﬁve patients had received high-dose chemotherapy and
53 standard-dose chemotherapy. Following surgery and chemother-
apy, 94 patients received locoregional radiotherapy. None of the
variables in Table 1 show an imbalance between patients in the
two treatment arms. During the study four patients in the standard
dose arm with severe depressive symptoms were offered a lower
dose of daily 20 mg tamoxifen but were not excluded from the
interview analysis. No other hormonal therapy was used during
the study.
Menopausal status
According to last menstrual period and serum hormone levels, 28%
of all patients were postmenopausal at the start of tamoxifen,
equally distributed over the treatment arms (Table 2). One year
after chemotherapy, during tamoxifen use, 61% of the patients
were postmenopausal, more often in the high-dose group (98%)
than in the standard-dose group (30%) (P50.01). During the
interview 3–6 months after tamoxifen was stopped, more patients
were postmenopausal in the high-dose group (96%) than in the
standard-dose group (33%) (P50.01).
Symptoms during tamoxifen
During the 2 years of tamoxifen treatment, the reported symptoms
stayed stable except for the gastrointestinal complaints which
disappeared after 1–3 months. We therefore show the symptoms
at 1 year of tamoxifen use (Table 3). Hot ﬂushes were experienced
by 86% of the patients during tamoxifen, not related to treatment
arm (Table 3). Fifty-four patients (55%) suffered from disruption
of sleep, i.e. awakening more than twice a night, which was not
related to the type of chemotherapy received, but showed a strong
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Table 1 Patient characteristics and prior treatment before tamoxifen
All patients Standard-dose High-dose
(n=98) (n=53) (n=45)
Median age in years (range) 45 (24–55) 45 (27–55) 46 (24–54)
Surgery
Lumpectomy 13 8 5
Mastectomy 85 45 40
Radiotherapy
Locoregional radiotherapy 94 51 43
No radiotherapy 4 2 2
Menopausal status
Premenopausal 71 38 33
Postmenopausal 27 15 12
Patients
Sexually active 94 50 44
Not sexually active 4 3 1
Table 2 Number of patients being postmenopausal at the start of
tamoxifen (n=98), after 1 year of tamoxifen (n=98) and 3–6 months after
cessation of tamoxifen (n=49)
All patients Standard-dose High-dose
All Postmp
a (%) All Postmp (%) All Postmp (%)
At start of tamoxifen 98 27 (28) 53 15 (28) 45 12 (27)
During tamoxifen 98 60 (61) 53 16 (30) 45 44 (98)
b
After tamoxifen 49 34 (69) 21 7 (33) 28 27 (96)
b
aPostmp=number of patients with postmenopausal status, based on no menstrual
periods in the preceding 12 months and FSH levels 430 nmol l
71 and oestradiol
levels 50.10 nmol l
71.
bP-value high-dose vs standard dose arm 50.05.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(10), 1546–1550relation with the occurrence of hot ﬂushes (P50.0005). Fifty-three
out of 83 patients (64%) with hot ﬂushes experienced disturbed
sleep with night sweats, vs only one patient without hot ﬂushes.
Forty patients (41%) reported difﬁculty concentrating during
tamoxifen treatment, a symptom which was not related to
chemotherapy regimen. However, disruption of sleep was asso-
ciated with concentration problems (P50.05). Irritability was
reported by 29% of the women and was related to difﬁculty
concentrating (P50.0005) and to disruption of sleep (P50.05).
Depressive symptoms were mentioned by 12% of the patients,
19% in the standard-dose and 4% in the high-dose arm
(P50.05) which led to discontinuation of tamoxifen use in two
and dose reduction to 20 mg in four patients.
Gastrointestinal symptoms during tamoxifen use were
mentioned by 43 patients (44%) at the beginning of tamoxifen,
and subsided in all patients with 1–3 months after starting
tamoxifen.
Sexual functioning during tamoxifen
Ninety-four patients had a sexual partner during tamoxifen of
whom 37 were pre- and 57 were postmenopausal after 1 year on
tamoxifen. Results are shown in Table 3. Vaginal dryness during
intercourse was mentioned by 40%, 34% in the standard-dose
and 48% in the high-dose arm (ns). Decreased sexual desire was
reported by 44% of the patients, which did not differ between
patients in the standard-dose and high-dose arm, or between
premenopausal and postmenopausal women. Decreased libido
was strongly related to a dry vagina (P50.0005) and dyspareunia
(P50.0005). These complaints led to decreased sexual activity in
28 out of 94 (30%) (10 pre- and 18 postmenopausal) patients. Five
patients were unable to be sexually active due to painful inter-
course or complete loss of sexual desire.
Symptoms after tamoxifen
Eighty-two patients were seen 3–6 months following the end of
tamoxifen treatment; 33 of them were not evaluable because of
disease progression and other treatment of which 15 were in the
high-dose and 18 in the standard-dose arm. Ten patients were still
using tamoxifen and six had withdrawn from the study. As a result
49 patients were disease-free during the interview after completion
of tamoxifen treatment, 21 in the standard-dose arm and 28 in the
high-dose arm, of whom 47 were sexually active. Paired samples of
symptoms reported during and after tamoxifen were analysed,
which showed an improvement in subjective symptoms for all cate-
gories 3–6 months after tamoxifen was stopped (Table 4). After
tamoxifen, hot ﬂushes, disturbed sleep and vaginal dryness were
more prevalent in the high-dose group (P50.05). All patients
who had reported depressive symptoms during tamoxifen
improved after tamoxifen was stopped.
DISCUSSION
In this study we evaluated subjective side effects and psychosexual
function, in relation to menopausal status, in breast cancer patients
receiving tamoxifen after standard-dose or high-dose chemother-
apy. Although this was not a placebo controlled trial, we are able
to draw some conclusions on the impact of tamoxifen use by
comparing data from interviews during and after tamoxifen use.
As we only included disease-free patients, they may show an
improvement in their well-being at the last interview, simply due
to the passage of time. To make this time effect as small as
possible, we held the last interview shortly (3–6 months) after
the discontinuation of tamoxifen.
Adjuvant therapy with daily 40 mg tamoxifen after chemother-
apy caused symptoms of which hot ﬂushes and impaired sexual
function were most prevalent. Hot ﬂushes was the most frequently
reported symptom, not only by postmenopausal but also by
premenopausal patients. For comparison, postmenopausal breast
cancer patients without adjuvant therapy report hot ﬂushes in
about 40% of the cases (Ragaz, 1997). In a recent study of 114
postmenopausal breast cancer patients, hot ﬂushes were reported
by 65% of the patients, of which 59% rated the symptoms as severe
(Carpenter et al, 1998). In our study hot ﬂushes coincided with
disturbed sleep and problems concentrating, which was not related
to type of chemotherapy or menopausal status. Van Dam et al
(1998) evaluated cognitive function by psycho-neurological tests
in patients who were randomly assigned to receive high-dose
(n=34) or standard-dose chemotherapy (n=36) plus 2 years tamox-
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Table 3 Number of patients reporting symptoms during tamoxifen
treatment (n=98)
All patients
Standard-
dose High-dose
Number (%) Number (%) Number (%)
All patients 98 (100) 53 (100) 45 (100)
Symptoms
Hot ﬂushes 83 (85) 42 (79) 41 (91)
Disturbed sleep 54 (55) 29 (55) 25 (56)
Difﬁculty concentrating 40 (41) 22 (42) 18 (40)
Depressive symptoms 12 (12) 10 (19) 2 (4)
a
Musculo-skeletal symptoms 42 (43) 23 (43) 19 (42)
Dry vagina 38 (40) 17 (34) 21 (48)
Dyspareunia 29 (30) 13 (24) 16 (36)
Decreased sexual desire 41 (44) 18 (36) 23 (52)
aP-value high-dose vs standard-dose 50.05.
Table 4 Prevalence of symptoms in paired patients, during and 3–6
months after tamoxifen
All patients Standard-dose High-dose
Number (%) Number (%) Number (%)
All patients 49 (100) 21 (100) 28 (100)
Symptoms
Hot ﬂushes 42 (86)
a 15 (71)
a 27 (96)
a,b
After 20 (41) 2 (10) 18 (64)
b
Sleep disturbances
During 29 (59)
a 10 (48)
a 19 (68)
a
After 7 (14) 1 (5) 6 (21)
b
Difﬁculty concentrating
During 21 (43)
a 7 (33)
a 14 (50)
a
After 4 (8) 1 (5) 3 (11)
Depressive symptoms
During 6 (12)
a 4 (19) 2 (7)
After 0 0 0
Musculo-skeletal symptoms
During 19 (39)
a 09 (43)
a 10 (36)
After 8 (16) 2 (10) 6 (21)
Dry vagina
During 21 (45)
a 5 (26) 16 (57)
After 12 (26) 1 (5) 11 (39)
b
Dyspareunia
During 16 (34)
a 6 (32) 10 (36)
After 10 (21) 4 (21) 6 (21)
Decreased sexual desire
During 24 (51)
a 8 (42) 16 (57)
a
After 13 (28) 3 (16) 10 (36)
aP-value 50.05 during vs after tamoxifen.
bP-value 50.05 high-dose vs standard-
dose.
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British Journal of Cancer (2002) 86(10), 1546–1550 ã 2002 Cancer Research UKifen 40 mg daily, and compared the results with those from 34
patients with stage I breast cancer treated with surgery but without
systemic therapy. Patients enrolled in their study were at least 6
months post-chemotherapy. The risk of cognitive impairment with
high-dose treated patients was 8.2 times higher than in breast
cancer patients not receiving systemic therapy and 3.5 times higher
than in standard-dose treated patients. The authors concluded that
impaired cognitive functioning as deﬁned by a battery of psycho-
neurological tests, may be a dose-limiting factor in high-dose
chemotherapy. In our study 41% of the patients reported concen-
tration problems during tamoxifen use, however equally distributed
over standard-dose and high-dose treated patients. Notwithstand-
ing, concentration problems were related to hot ﬂushes and
disturbed sleep and in both treatment groups these symptoms
showed an improvement after stopping tamoxifen, suggesting that
concentration problems in these patients may, at least in part, be
due to tamoxifen. The higher cognitive impairment in the high-
dose group in the study of van Dam might be explained by the
chemotherapy induced menopause in these patients.
Depressive symptoms were mentioned by 12% of the patients,
more often after standard-dose (19%) than high-dose chemother-
apy (4%). We hypothesise that this difference between the two
treatment groups might be related to menopausal status of the
patients and hence the agonistic/antagonistic effect of tamoxifen.
As depression and mood-ﬂuctuations may be related to oestro-
gen-deprivation, depressive symptoms in our study may be
related to the anti-oestrogenic effect of tamoxifen in the predomi-
nantly premenopausal patients of the standard-dose group, while in
the menopausal patients in the high-dose group, tamoxifen acts as
an oestrogen agonist. In the placebo-controlled NSABP-prevention-
trial, Day et al (1999) reported that tamoxifen was not associated
with depression in a cohort of healthy women who received
20 mg tamoxifen daily for the prevention of breast cancer. The
difference between their data and ours could be a result of the
higher tamoxifen dose in our study, as dose reduction from 40
to 20 mg daily in four depressed patients in our study, resulted
in amelioration of their depressive symptoms.
Breast surgery and chemotherapy-induced menopause can
interfere with self-esteem and sexual function of women (Ganz
et al, 1992, 1998; Schover, 1994; Meyerowitz et al, 1999). This
raises the problem of how to measure the effect of tamoxifen
on sexual function, considering several causative factors, while
no baseline questionnaires are available. Consequently, not the
actual level of sexual activity but the changes compared to the
situation without tamoxifen treatment are of interest. In order
to determine a change in sexual function we evaluated three
factors determining sexual function: sexual desire, sexual activity,
and pain or discomfort during intercourse. These aspects are also
addressed in the recently developed Sexual Activity Question-
naire, which was designed to investigate the impact of long-
term tamoxifen use on the sexual function of women in a
prevention trial (Thirlaway et al, 1996). Forty-four per cent of
our patients reported a decreased interest in sexual activity
during tamoxifen therapy, unrelated to the type of previous
chemotherapy or menopausal status and this might also be an
effect of breast cancer diagnosis and the other treatment modal-
ities. However, after tamoxifen was stopped, patients in the high-
dose arm reported sexual dysfunction more often (36%) than
patients in the standard-dose arm (16%). In early stage breast
cancer patients, changes in sexual function are more prevalent
in women with ovarian failure due to adjuvant chemotherapy
than in women with a premenopausal status (Lindley et al,
1998). Ganz et al (1998) observed impaired sexual function in
women who became postmenopausal, compared to those who
retained menstrual cycles, while no effect on sexual function
was seen of tamoxifen when added to chemotherapy in the Ganz
study, or in another recent study (Berglund et al, 2001). On the
contrary, Kaplan (1992) suggested that the addition of tamoxi-
fen to chemotherapy exacerbates its sexual side effects. Ganz et al
(1998) observed impaired sexual function in women who became
postmenopausal, compared to those who retained menstrual
cycles. In our study, 67% of the patients with induced meno-
pause reported impaired sexual function during tamoxifen,
compared to 49% premenopausal patients (data not shown),
pointing to an additional effect of induced menopause over
the effect of tamoxifen. All except one of these 33 ‘new’ post-
menopausal patients had received high-dose chemotherapy.
Meyerowitz et al (1999) reported that a negative impact from
breast cancer diagnosis and treatment on sexuality was most
likely in patients who experienced changes in hormonal status.
We found a relationship between loss of sexual desire, vaginal
dryness and painful intercourse, symptoms that are also
frequently reported by healthy women during menopause
(McCoy and Davidson, 1985; Greendale et al, 1996). In our
study however, these symptoms were also reported by premeno-
pausal patients during tamoxifen, suggesting a direct anti-
oestrogenic effect of tamoxifen on the vaginal epithelium in these
young women.
The relative impact as well as the cumulative impact of adjuvant
tamoxifen and chemotherapy on patient well being is an important
and neglected topic. Our data indicate that 40 mg tamoxifen daily,
following chemotherapy, interferes with psychosexual well-being,
causing different side effects of which hot ﬂushes and impaired
sexual function are most frequent, both in pre- and postmenopau-
sal women. We suggest that induced menopause due to adjuvant
high-dose chemotherapy might explain why symptoms did not
fully recover in all patients, after ﬁnishing tamoxifen treatment.
Therefore, in this study of breast cancer patients younger than
56 years at diagnosis, symptoms are most probably especially due
to a combined effect of tamoxifen and the hormonal change
induced by high-dose chemotherapy. This is the ﬁrst study in
which side effects are shown to be clustered and it is also the ﬁrst
study about side effects of breast cancer treatment in clearly
deﬁned pre- and postmenopausal women, in which menopausal
status was deﬁned not only by the last menstrual period but also
by serum levels of FSH and oestradiol. Tamoxifen predominantly
acts as an anti-oestrogen in premenopausal women, with recovery
of symptoms after its cessation. In postmenopausal women tamox-
ifen predominantly acts as an oestrogen, but is not sufﬁcient to
alleviate menopausal symptoms in women with chemotherapy
induced menopause.
This knowledge allows the clinician to inform patients about the
side effects, including the sexual sequelae, both of tamoxifen use
and (high-dose) chemotherapy, and to bring up the subject during
follow-up visits. Subjective and psychosexual well-being in breast
cancer patients should be further investigated with the ultimate
goal of acknowledging the impact of breast cancer therapy, and
to develop interventions to minimise side effects.
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APPENDIX 1–Interview list of self reported symptoms
Vasomotor symptoms
Hot ﬂushes
Sweating
Clammy hands
Fluid retention
Swollen hands or feet
Sleeping problems
Difﬁculty falling asleep
Difﬁculty staying asleep
Nightly awakenings two or
more times a night
Mood attribute
Irritability
Restlessness
Anxiety/fears
Concentration problems
Depressed mood
Feeling miserable and sad
Lack of enjoyment
Loss of interest
Loss of vitality
Loss of initiative
Life not worth living
Musculo-skeletal
Joint pain
Bone pain
Muscle cramps
Muscle stiffness
Muscle weakness
Gastrointestinal attribute
Nausea
Vomiting
Pyrosis
Dyspepsia
Headaches
Others
APPENDIX 2–Interview items about sexual functioning
‘Did you have any sexual activity in the past 6 months?’ Yes/No
If ‘yes’:
Since tamoxifen, did you experience:
– Impaired sexual interest Yes/No
– Loss of desire Yes/No
– Vaginal dryness Yes/No
– Painful intercourse Yes/No
– Less frequent sexual activity due to loss of libido Yes/No
– Less frequent intercourse due to pain Yes/No
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